期刊文献+

实验性肺癌尿激酶型纤溶酶原激活物和抑制物的表达及意义

SIGNIFICANCE AND EXPRESSION OF UROKINASE TYPE PLASMINOGEN ACTIVATOR AND PLASMINOGEN ACTIVATOR INHIBITOR IN EXPERIMENTAL LUNG CANCER
下载PDF
导出
摘要 目的研究尿激酶型纤溶酶原激活物 (urokinasetypeplasminogenactivator,uPA)和抑制物 1(PAinhibitor,PAI 1)在实验性肺癌的发生、发展及侵袭转移过程中的作用。方法将Lewis肺癌瘤株腹腔注射C5 7/BL小鼠 ,于接种后 9、17、2 3天各处死 6只 ,取瘤、肺组织匀浆 ,低温离心取上清液 ,采用酶联免疫吸附 (enzyme likedimmunosorbentassay ,ELISA)法检测血浆和组织中uPA和PAI 1的含量 ,按环磷酰胺 +刺五加组、环磷酰胺组、刺五加组、肿瘤对照组和正常对照组分别进行对比分析。结果肿瘤组uPA和PAI 1含量高于正常对照组 ;环磷酰胺 +刺五加组血浆、瘤和肺组织中uPA和pAI 1活性低于肿瘤组。结论检测实验性肺癌uPA和PAI 1含量可能对其侵袭转移。 ObjectiveTo investigate the expression of urokinase type plasminogen activator(uPA) and PA inhibitor-1(PAI-1) in occurrence, progression and invasion of experimental lung cancer. MethodsC57/BL mice were inoculated with Lewis lung cancer strain, on 9, 17, 23 day post-inoculation, respectively, six mice were killed and the lung, tumor were removed aseptically. The plasma and tissues of the mice were homogenized, frozen and cleared of cellular debris by low speed centrifugation. The levels of uPA and PAI-1 of plasma and tissue were detected by ELISA in Lewis lung cancer C57/BL mice. The differences were compared between five groups as acanthopanax senticous plus cyclosphamide group, cyclophosphamid group, tumor control group and normal control group. ResultsThe levels of uPA and PAI-1 from tumor control group were higher than those from normal control group. The levels of uPA and PAI-1 in plasma and tumor from acanthopanax senticous plus cyclosphamide group were lower than those from tumor control group. ConclusionDetection of uPA and PAI-1 levels in experimental lung cancer may have certain referential value in evaluation of cancer invasion, metastasis and the prognosis.
出处 《河北医科大学学报》 CAS 2005年第1期12-15,共4页 Journal of Hebei Medical University
基金 河北省自然科学基金资助 ( 3 993 92 )
关键词 肺肿瘤 尿激酶 肿瘤转移 预后 小鼠 lung neoplasms urokinase neoplasm metastasis prognosis mice
  • 相关文献

参考文献8

  • 1郑起,汤钊猷,吴志全,施达仁,宋后燕.纤溶酶原激活物抑制物1与肝细胞癌[J].中华外科杂志,1998,36(8):474-476. 被引量:6
  • 2李攻戌,林洪生,李树奇,赵钟宽,裴迎霞,祁鑫,朴炳奎.基质降解酶u-PA,PAI-1与人肺癌细胞浸润转移的相关关系的研究[J].中国肿瘤临床,1998,25(10):760-763. 被引量:1
  • 3徐霞,彭黎明.尿激酶型纤溶酶原激活物受体与肿瘤[J].肿瘤,2003,23(1):81-83. 被引量:4
  • 4Gerstein ES. Shcherbakov AI, Kazmin AI, et al. Urokinase and tissue type plasminogen activators and their typ-1 inhibitor(PAI-1) in gastric cancer[J]. Vopr Onkol. 2003, 49(2): 165-169.
  • 5Horn LC, Pipping S, Raptis G. et al. Clinical relevance of urokinase type plasminogen activator and its inhibitor type I(PAI-1) in squamous cell carainoma of the uterine cervix[J].Aust J Obstet Gynaecol, 2002, 42(42): 383-386.
  • 6Konno H, Abe J, Kaneko T. et al. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer [J].Cance Res.2001,92(5): 516-523.
  • 7Shinji N. Ken IH, Minoru F. et al. Involvement of vascular endothelial growth factor and uPA in microvessel in invasion in human colorectal cancer [J]. Int J Cancer. 1998, 79(2): 179-186.
  • 8Okusa Y. Ichikura T. Mochinuki H. et al. Prognostic of stromal cell derived urokinase type plasminogen activator in gastric carcinoma [J]. Cancer, 1999. 85(5): 1033-1038.

二级参考文献22

  • 1[1]Andreasen PA, Kjoler L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review [J].Int J Cancer, 1997,72:l
  • 2[2]Bell WR. The fibrinolytic system in neoplasia [J]. Semin Thromb Hemost, 1996,22:459
  • 3[3]Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator receptor(CD87) is a pleiotropic molecule [J]. Eur J Biochem, 1998,252:185
  • 4[4]Ossowski L, Aguirre-Ghiso .JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth [J]. Curr Opin Cell Biol,2000,12:613
  • 5[5]Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis:prognostic relevance and target for therapy [J]. Thromb Hemost,1997,78:285
  • 6[6]Huang S, New L, Pan ZX, et al. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogenactivated protein kinase activity [J]. J Biol Chem,2000,275:12266
  • 7[7]Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels[J]. Cancer Res,1993,53:3198
  • 8[8]Jard M, Ingl s-Esteve J, Burgal M, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells[J]. Thromb Hemost, 1996,76:1009
  • 9[9]Petro GD, Tavian D, Copeta A, et al. Expression of urokinase-type plasminogen activator (uPA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma [J]. Cancer Res,1998,58:2234
  • 10[10]Duggan C, Maguire T, Mcdermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer[J]. Int J Cancer 1995,61:597

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部